safety

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, Sauk JS. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the[...]

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Khalid A, Balach R, Rasool A, Daniyal SM, Nizami MT, Gul I, Naqvi A, Fonarow GC, Waqas SA. Clinical outcomes and safety of SGLT2 inhibitors[...]

Hsue PY, Behrens GMN, Xu ZJ, Zhao Y, Cmar J, Lahoulou R, Campo RE, Plank RM. Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD)[...]

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study[...]

Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel[...]

Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP,[...]

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with[...]

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats[...]